삼성서울병원

Ko En

Hematology-Oncology Park, Joon Oh M.D , M.D., Ph.D

Expertise
Pancreatic cancer, Biliary tract cancer
Treament Schedule 04 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
AM
PM
Treament Schedule 05 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

1996~2001 Ph.D. in Medicine Yonsei University Graduate School of Medical Science, Seoul, Korea
1993~1995 Master in Medicine Yonsei University Graduate School of Medical Science, Seoul, Korea
1985~1991 MD Yonsei University College of Medicine, Seoul, Korea

Post-Graduate Training

Fellowship   2001~2002 Clinical Fellowship Samsung Medical Center, Sungkyunkwan University School of Medicine
1999~2001 Clinical & Research Fellowship Yonsei Cancer Center, Yonsei Univ. Medical College
Residency   1992~1996 Yonsei Severance Hospital, Yonsei Univ. Medical College, Seoul, Korea
Internship   1991~1992 Yonsei Severance Hospital, Yonsei Univ. Medical College, Seoul, Korea

Professional Appointments

2019~Present Director Director, Precision Medicine Research Center, Samsung Research Institute for Future Medicine, Seoul, Korea
2015~2021 Director Center for Rare Cancers, Samsung Comprehensive Cancer Center, Seoul, Korea
2013~Present Professor Div. of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2007~2013 Associate Professor Div. of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2006~2008 Postdoc. Fellowhsip Dana-Farber Cancer Inst. /Harvard Medical School, Boston, MA
2003~2007 Assistant Professor Div. of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2002~2003 Clinical Assistant Professor Div. of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Professional Memberships

2022~Present Active member European Society of Medical Oncology (ESMO)
1999~Present Active member American Society of Clinical Oncology (ASCO)
2002~Present Active member American Association of Cancer Research (AACR)
2005~Present Active member Korean Society of Medical Oncology (KSMO)
2001~Present Active member Korean Cancer Study Group (KCSG)
1995~Present Active member Korean Cancer Association
1992~Present Active member Korean Association of Internal Medicine

Selected Publications

  • J HEPATO-BIL-PAN SCI 2021 10.1002/jhbp.986 Multi-biomarker panel prediction model for diagnosis of pancreatic cancer Lee1, DH; Yoon, W; Lee, A; Han, Y; Byun, Y; Kang, JS; Kim, H; Kwon, W; Suh, YA; Choi, Y; Namkung, J; Han, S; Yi, SG; Heo, JS; Han, IW; Park, JO; Park, JK; Kim, SC; Jun, E; Kang, CM; Lee, WJ; Lee, HK; Lee, H; Lee, S; Jeong, SY; Lee, KE; Han, W; Park, T; Jang, JY
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100049 Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.02232 Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) Hecht1, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY
    View PubMed
  • CANCERS 2021 10.3390/cancers13071647 Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review Yoo1, C; Shin, SH; Park, JO; Kim, KP; Jeong, JH; Ryoo, BY; Lee, W; Song, KB; Hwang, DW; Park, JH; Lee, JH
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed